Candidiasis among non-neutropenic patients: From colonization to infection;Candidoses du sujet non neutropénique: De la colonisation à l'infection

Annales Francaises d'Anesthesie et de Reanimation

Volumn 20, Issue 4, 2001, Pages 382-388

  Eggimann, P ^a   Pittet, D ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Candida albicans; Candidemia; Candidiasis; Colonization; Epidemiology; Nosocomial infections; Prophylaxis; Treatment

Indexed keywords

AMPHOTERICIN B; TRIAZOLE DERIVATIVE;

CANDIDA ALBICANS; CANDIDIASIS; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE; MORTALITY; NEUTROPENIA; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SEPTIC SHOCK;

EID: 0035007043     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0750-7658(01)00374-4     Document Type: Article

References (44)

1. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals
2. Candida colonization and subsequent infections in critically ill surgical patients
3. Secular trends in the epidemiology of nosocomial fungal infections in the United States, -1990 National Nosocomial Infections Surveillance System
4. Clinical significance of Candida isolated from peritoneum in surgical patients
5. Hospital infections
6. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
7. Epidemiology of Candidemia-a nationwide survey in Israel
8. National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units
9. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study
10. Nosocomial infections in medical intensive care units in the United States
11. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
12. The epidemiology of hematogenous candidiasis by different Candida species
13. International surveillance of blood stream infections due to Candida species in the European Sentry Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
14. Bloodstream infections due to Candida species: Sentry antimicrobial surveillance program in North America and Latin America, 1997-1998
15. Hospital-acquired candidemia. The attributable mortality and excess length of stay
16. Microbiological factors influencing the outcome of nosocomial bloodstream infections. A six year validated, population-based model
17. Association of secondary and polymicrobial nosocomial bloodstream infections with higher mortality
18. Gastrointestinal colonization with yeast species and Candida septicemia in very low birth weight infants
19. Evidence of nosocomial spread of Candida albicans causing bloodstream infection in a neonatal intensive care unit
20. A study of a hospital cluster of systemic candidosis using DNA typing methods
21. Risk factors for hospital-acquired candidemia. A matched case-control study
22. Risk factors for candidemia in patients with acute lymphocytic leukemia
23. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe
24. The role of Candida in intraperitoneal infections
25. Primary Candida pneumonia. Experience at a large center cancer and review of the literature
26. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
27. Nosocomial candidemia: Risk factors and attributable mortality
28. Predictors of adverse outcome in cancer patients with candidemia
29. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
30. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
31. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study
32. The role of Candida sp isolated from bronchoscopic samples in non-neutropenic patients
33. International conference for the development of a consensus on the management and prevention of severe candidal infections
34. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study
35. Peritonitis into the 1990s: Changing pathogens and changing strategies in the critically ill
36. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans
37. The risk of positive cultures for Candida in the critically ill patient
38. High-dose fluconazole therapy in patients with severe fungal infections
39. Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo
40. Laboratory diagnosis of invasive candidiasis
41. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: Useful combined test for diagnosis of systemic candidiasis
42. Detection and identification of fungal pathogens in blood by using molecular probes
43. When to start antifungal therapy in the nonneutropenic critically ill?
44. Management of deep Candida infection in surgical and intensive care unit patients